Skip to main content
. 2019 Aug 15;12:6549–6554. doi: 10.2147/OTT.S205674

Figure 1.

Figure 1

Progression-free survival of patients who treated with anlotinib (A) 46 patients received anlotinib treatment, 3.3 months, 95% CI: 1.595-5.071; (B) for patients receiving anlotinib as third line therapy vs. as further line therapy, 2.8 vs. 4.0 months (P=0.540).